<DOC>
	<DOCNO>NCT00004161</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development treat early cancer . Fenretinide may effective drug treat leukoplakia . PURPOSE : Randomized phase II trial study effectiveness fenretinide treat patient leukoplakia mouth .</brief_summary>
	<brief_title>Fenretinide Treating Patients With Leukoplakia Mouth</brief_title>
	<detailed_description>OBJECTIVES : I . Determine modulation fenretinide surrogate endpoint marker oral mucosal carcinogenesis patient oral dysplastic leukoplakia . II . Determine whether fenretinide cause significant modulation intermediate endpoint marker significant regression oral dysplastic leukoplakia patient population . III . Compare ability fenretinide placebo modulate surrogate endpoint biomarkers patient population . IV . Document degree recurrence oral dysplastic leukoplakia administration fenretinide , site new site . OUTLINE : This randomize , double blind , placebo control study . Patients randomize 1 2 treatment arm : Arm I : Patients receive oral fenretinide daily ( except day 1-3 month ) 6 month . Arm II : Patients receive oral placebo daily ( except day 1-3 month ) 6 month . Patients receive oral fenretinide daily ( except day 1-3 month ) 6 month . Patients follow every 3 month . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Leukoplakia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven dysplastic leukoplakia great 1 cm diameter PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 125,000/mm3 Hemoglobin least 12.0 g/dL Hepatic : Bilirubin le 1.5 mg/dL SGOT le 2 time upper limit normal ( ULN ) Renal : Creatinine le 1.7 mg/dL Cardiovascular : No symptomatic coronary artery disease No uncontrolled hypertension No prior coronary artery bypass No acute myocardial infarction past year Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 1 month prior , , 12 month study Fasting serum triglyceride less 2 time ULN Cholesterol le 350 mg/dL No hypersensitivity vitamin A retinoids No active malignancy No concurrent acute chronic medical psychiatric condition would preclude compliance toxicity assessment No concurrent severe night blindness PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 3 month since prior chronic high dose ( great 30,000 IU/day ) vitamin A ( retinol ) At least 1 month since prior retinoids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>lip oral cavity cancer</keyword>
</DOC>